CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 95 enrolled
Drug / intervention
Pioglitazone +1 moredrug
Likely dose
Pioglitazone 15mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01301027
NCT01301027N/ACompleted
CompareCT.gov

Effects of Pioglitazone on Adiponectin and Inflammatory Markers in Overweight or Obese Hemodialysis Patients: A Double-Blinded Randomized Controlled Trial

University of Utah·interventional·Posted Feb 23, 2011·Updated Oct 3, 2016

In Brief

A clinical study evaluating Pioglitazone and Placebo for End Stage Renal Disease. Completed, enrolled 95 participants across 2 sites.

Detailed Summary

This is a double blinded randomized clinical trial of pioglitazone vs. placebo in overweight or obese, diabetic and non-diabetic hemodialysis patients. This study will examine whether pioglitazone modulates adipokine production by adipose tissue in hemodialysis patients and whether these changes result in reduction of inflammation, insulin resistance and oxidative stress and increase in muscle mass. In addition, this study will also examine the associations of adiposity with adipokines and the metabolic milieu in hemodialysis patients to better understand the biology of adipocytes in uremic milieu.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnd Stage Renal Disease
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Colorado, Denver

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 23, 2011
Enrollment StartMay 1, 2008
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.6 yearsPosted 15.4 years ago

Interventions

Pioglitazonedrug

15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks

Placebodrug

1 pill a day for 26 weeks